Please Wait.....
Report
Global Markets and Technologies for Advanced Drug Delivery Systems
Market Research Report I 2024-02-06 I 265 Pages I BCC Research
Description
Report Scope:
This report aims to provide a comprehensive study of the global market for advanced drug delivery systems (ADDS) and processes, both in terms of quantitative and qualitative data, to help people and companies develop business/growth strategies, assess the market landscape, analyze their position in the current marketplace and make informed business decisions about drug deliveries.
This in-depth analysis of the global ADDS market includes historical data and market projections on sales by technology, route of administration, drug vehicles/carriers and application. The analysis describes the different types of ADDS technology (immediate-release drug delivery, extended-release drug delivery, targeted-release drug delivery, delayed-release drug delivery, and pulsatile-release drug delivery) and their current and historical market revenues. It also covers the route of administration of a drug delivery system and the source of a carrier mechanism for drug delivery. In addition, the report examines applications of ADDS (oncology, respiratory, inflammatory and allergies, cardiovascular, ophthalmic, central nervous system, hormone replacement therapy and gynecology, viral and bacterial diseases, diabetes, urology, gastrointestinal disorders, dermatology, other).
The geographic scope of this study covers the U.S. and companies worldwide. The report identifies the main elements of advanced drug delivery products and trends in different industries.
Report Includes:
- 27 data tables and 93 additional tables
- An overview of the global markets and technologies for advanced drug delivery systems (ADDS)
- Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
- Estimate of the market size and revenue forecast for the global ADDS market, and corresponding market share analysis based on technology, application (therapeutic area), route of administration, vehicle/carrier of drugs mechanism and geographic region
- Facts and figures pertaining to the market drivers, opportunities and challenges, emerging technologies and regulatory landscape
- Discussion of the importance of ESG in the ADDS market, including consumer attitudes, impact of ESG factors on company performance and ESG practices of leading companies
- Review of patents and patent applications filed on drug delivery release mechanisms and novel applications
- Insight into the emerging technologies and developments in the ADDS market and clinical trial landscape
- An analysis of the industry structure, including company market shares, recent M&A activity and venture funding
- Analysis of the competitive landscape based on recent developments and the segmental revenues of leading vendors
- Company profiles of major players within the industry, including Johnson & Johnson, Novartis AG, Pfizer Inc., Merck & Co. Inc., Medtronic, and Abbott.
Executive Summary
Summary:
The global market for advanced drug delivery systems was valued at $REDACTED billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED% from $REDACTED billion in 2023 to reach $REDACTED billion through 2028. Advances in therapeutics, the high prevalence of chronic diseases and rising innovations in material science will drive growth in this market. However, the advanced drug delivery systems (ADDS) market's growth will be hampered by a low acceptance of nanoparticles due to their potential risks and environmental concerns.
Based on technology, the advanced drug delivery systems (ADDS) market is segmented into immediate-release drug delivery, extended-release drug delivery, targeted-release drug delivery, delayed-release drug delivery, pulsatile-release drug delivery. Extended-release drug delivery dominates the market due to its usage in managing complex chronic diseases. The extended-release formulations offer enhanced patient adherence, more effective life-cycle management of pharmaceuticals and more long-term relief of symptoms by minimizing fluctuations in drug levels.
Based on the route of administration, the advanced drug delivery systems (ADDS) market is segmented into oral, parenteral/injectable, transmucosal, implant, transdermal, topical. The oral segment dominates the market. This can be attributed to the widespread use of the oral route in drug delivery due to the benefits associated with oral administration, including cost-effectiveness, minimal sterility constraints, flexibility in dosage form design and ease of production.
Based on drug vehicles/carriers, the ADDS market is segmented into nanoparticles, monoclonal antibodies, liposomes, polymer therapeutics, prodrugs, microparticles, other. The monoclonal antibodies segment will witness the highest CAGR due to the increasing incidence of cancers.
ADDS market has been segmented into oncology, respiratory, inflammatory and allergies, cardiovascular, ophthalmic, central nervous system, hormone replacement therapy and gynecology, viral and bacterial diseases, diabetes, urology, gastrointestinal disorders, dermatology, other based on application. The diabetes segment is poised to experience the highest CAGR due to the increasing incidence of diabetes and the introduction of smart insulin delivery devices in the market.
Some key players in this market include Johnson & Johnson, Novartis, Roche, Pfizer, Merck & Co., Medtronic and Abbott.
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in this Update?
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Highlights of the Market for Advanced Drug Delivery Systems
Chapter 3 Market Overview
Overview
Evolution of Advanced Drug Delivery Systems
Chapter 4 Market Dynamics
Overview
Market Drivers
Market Restraints
Market Opportunities
Impact of COVID-19 on the ADDS Market
Chapter 5 Evaluation of the Market Based on Technology
Overview of Advanced Drug Delivery Systems and Technologies
Market Share and Forecast
Immediate-Release Drug Delivery
Extended-Release Drug Delivery
Targeted-Release Drug Delivery
Delayed-Release Drug Delivery
Pulsatile-Release Drug Delivery
Chapter 6 Evaluation of the Market Based on Route of Administration
Overview of Routes of Administration of Drugs
Market Share and Forecast
Oral
Parenteral/Injectable
Transmucosal
Transmucosal Nasal and Pulmonary
Transmucosal Ocular
Transmucosal Rectal
Transmucosal Oral Buccal
Transmucosal Vaginal
Implant
Transdermal
Topical
Chapter 7 Evaluation of the Market Based on Vehicle/Carrier
Overview of Vehicles/Carriers Used in Advanced Drug Delivery Systems
Market Share and Forecast
Nanoparticles
Monoclonal Antibodies
Liposomes
Polymeric Therapeutics
Dendrimers
Polymeric Drug
Polymeric Micelles
Prodrugs
Microparticles
Others
Chapter 8 Evaluation of the Market Based on Application
Overview of Applications Used in Advanced Drug Delivery Systems
Market Share and Forecast
Oncology
Inflammatory Diseases and Allergies
Cardiovascular
Ophthalmic
Central Nervous System
Hormone Replacement Therapy and Gynecology
Viral and Bacterial Diseases
Diabetes
Urology
Gastrointestinal (GI) Disorders
Dermatology
Respiratory
Other Therapeutic
Chapter 9 Evaluation of the Market Based on Geographic Region
Global Market for ADDS by Region
North America
Europe
Asia-Pacific
Rest of the World (RoW)
Chapter 10 ESG Development
Introduction to ESG
Sustainability in the Advanced Drug Delivery Systems (ADDS) Industry: An ESG Perspective
Key ESG Issues
ESG Risk Rankings
Consumer Attitudes toward ESG in the ADDS Market
Case Study
Concluding Remarks from BCC
Chapter 11 Emerging Technologies in the Market
Emerging Technology, ADDS Market
3D Printing Technology in Drug Delivery
Biologics Drug Delivery
AI in Drug Delivery
Smart Drug Delivery System
Chapter 12 Clinical Trials and Patent Analysis
Clinical Trials Analysis
Clinical Trials Analysis by Type of Study
Clinical Trials Analysis by Status
Clinical Trials Analysis by Phase
Clinical Trials Analysis by Region
Patent Analysis
Patents by Year
Patents by Top Applicant
Patents by Top Owner
Patents by Jurisdiction
Chapter 13 Competitive Intelligence
Market Share Analysis
Recent Developments of Key Market Players
Chapter 14 Company Profiles
ABBOTT
ABBVIE INC.
ASTRAZENECA
BD
BOSTON SCIENTIFIC CORP.
F. HOFFMANN-LA ROCHE LTD
JOHNSON & JOHNSON SERVICES INC.
KINDEVA DRUG DELIVERY
MEDTRONIC
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI S.A.
TERUMO CORP.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 15 Appendix: Acronyms
List of Tables
Summary Table A : Global Market for Advanced Drug Delivery Systems, by Technology, Through 2028
Summary Table B : Global Market for Advanced Drug Delivery Systems, by Region, Through 2028
Table 1 : Global Market for Advanced Drug Delivery Systems, by Technology, Through 2028
Table 2 : Main Orally Disintegrating Drug Delivery Technologies
Table 3 : Comparison of Different Orally Disintegrating Drug Delivery Technologies
Table 4 : Drugs Qualified for Fast-Dissolving Tablet
Table 5 : Examples of Drugs Using Orally Disintegrating Drug Delivery Technologies
Table 6 : List of Commercially Available Fast Dissolving Tablets (FDTs)
Table 7 : List of Commercially Available Fast Dissolving Oral Films
Table 8 : Difference Between Sustained vs. Controlled Drug Delivery
Table 9 : Classic Methods of Extended-Release Delivery Systems and Their Limitations
Table 10 : Examples of Companies Developing Extended Drug Delivery Systems
Table 11 : Global Market for Extended-Release Drug Delivery Systems, by Type, Through 2028
Table 12 : Examples of Delivery Carriers for Targeted Drug Delivery Systems
Table 13 : Examples of FDA-Approved ADC Drugs
Table 14 : Examples of Current U.S. FDA-Approved Nanoparticles and Type of Targeting Employed, Indications, Advantages and Drawbacks
Table 15 : Examples of Companies Developing Targeted Drug Delivery Systems
Table 16 : Examples of Diseases that Require Pulsatile Drug Delivery Systems
Table 17 : Examples of FDA-Approved Advanced Pulsatile Drug Delivery Systems
Table 18 : Examples of Pulsatile Drug Delivery Systems on the Market and the Market Players That Developed Them
Table 19 : Advantages and Disadvantages of Different Routes of Drug Administration
Table 20 : Global Market for Advanced Drug Delivery Systems, by Route of Administration, Through 2028
Table 21 : Some Oral Advanced Drug Delivery Systems
Table 22 : Examples of Specialized Parenteral Routes of Administration
Table 23 : Transmucosal Drug Delivery
Table 24 : Global Market for Advanced Transmucosal Drug Delivery Systems, by Type, Through 2028
Table 25 : Global Market for Advanced Transmucosal Nasal and Pulmonary Drug Delivery Systems, Through 2028
Table 26 : Examples of Hydrogels and Composites Developed for Ocular Drug Delivery
Table 27 : Global Market for Advanced Ocular Advanced Drug Delivery Systems, Through 2028
Table 28 : Examples of Rectal Formulations Clinically Approved
Table 29 : Global Market for Advanced Rectal Advanced Drug Delivery Systems, Through 2028
Table 30 : Examples of Marketed Medications Delivered, by the Oral-Buccal Route of Administration
Table 31 : Global Market for Advanced Oral Buccal Drug Delivery Systems, Through 2028
Table 32 : Global Market for Advanced Vaginal Drug Delivery Systems, Through 2028
Table 33 : Examples of Implantable Drug Devices on the Market
Table 34 : FDA-Approved Transdermal Patches
Table 35 : Types of Topical Medications
Table 36 : Examples of Advanced Topical Drug Delivery Systems In Clinical Use
Table 37 : Global Market for Advanced Drug Delivery Systems, by Drug Delivery Vehicle/Carrier, Through 2028
Table 38 : Examples of Nanocarriers in Drug Delivery and Their Characteristics
Table 39 : Examples of FDA-Approved Nanodrugs Available for Clinical Use
Table 40 : Examples of Clinically Approved Liposome-Based Therapeutics on the Market
Table 41 : Some Liposomal Products Approved, by FDA and EMA
Table 42 : Global Market for Polymeric Therapeutics for Advanced Drug Delivery Devices, Through 2028
Table 43 : Examples of Dendrimer-Drug Interactions in Cancer Therapy
Table 44 : Examples of Polymer Drugs Commercially Available
Table 45 : Global Market Shares of Advanced Drug Delivery Systems, by Type of Polymeric Drug, 2022
Table 46 : Examples of Stimuli-Responsive Polymeric Micelles for Cancer Therapy
Table 47 : Examples of FDA-Approved Prodrugs on the Market
Table 48 : Comparison of Control Release Devices
Table 49 : Ten Leading Causes of Death Globally, 2021
Table 50 : Global Market for Advanced Drug Delivery Systems, by Application, Through 2028
Table 51 : Worldwide Cancer Incidence, by Type, 2020
Table 52 : Examples of Different Systems Used in the Cardiovascular Delivery of Therapeutics
Table 53 : Examples of Ophthalmology Drug Delivery Systems
Table 54 : Examples of Marketed Nanopharmaceuticals for Brain Disorders
Table 55 : Examples of Nanoplatforms for Drug Delivery Approved, by the FDA, EMA and Other Organizations
Table 56 : Examples of Antibacterial Drug Delivery Systems
Table 57 : Key Facts and Latest Data for Diabetes Globally, 2021 and 2045
Table 58 : Commercially Available Insulin Injector Pens & Manufacturers
Table 59 : Examples of Drug Delivery Systems for Diabetes Treatment
Table 60 : Prevalence of End Stage Renal Disease, by Country, 2020
Table 61 : Examples of Gastro-Retentive Products Available in the Market
Table 62 : Global Market for Advanced Drug Delivery Systems, by Region, Through 2028
Table 63 : Cancer Incidence in Europe, by Select Countries, 2022
Table 64 : ESG: Environmental Overview
Table 65 : ESG: Social Overview
Table 66 : ESG: Governance Overview
Table 67 : ESG Rankings for Major ADDS Companies, 2023*
Table 68 : Research Projects Using 3D Printing Techniques to Design Drug Delivery Systems
Table 69 : List of Smart Drug Delivery Systems
Table 70 : Clinical Trials in Drug Delivery System, by Type of Study, as of November 2023
Table 71 : Clinical Trials in Drug Delivery System, by Status, as of November 2023
Table 72 : Clinical Trials in Drug Delivery System, by Phase, as of November 2023
Table 73 : Clinical Trials in Drug Delivery System, by Region, November 2023
Table 74 : Patents Granted for Drug Delivery Systems, by Top Applicant, 2018-2022
Table 75 : Patents Granted for Drug Delivery Systems, by Top Owner, 2018-2022
Table 76 : Patents Granted for Drug Delivery Systems, by Jurisdiction, 2018-2022
Table 77 : Advanced Drug Delivery Systems: Market Player Ranking
Table 78 : Recent Developments in Global Market for Advanced Drug Delivery Systems, 2020-2023
Table 79 : Abbott: Company Snapshot
Table 80 : Abbott: Financials, 2021 and 2022
Table 81 : Abbott: Product Portfolio
Table 82 : Abbott: Key Developments, 2021
Table 83 : AbbVie Inc.: Company Snapshot
Table 84 : AbbVie Inc.: Financials, 2021 and 2022
Table 85 : AbbVie Inc.: Key Developments, 2020
Table 86 : AstraZeneca: Company Snapshot
Table 87 : BD: Company Snapshot
Table 88 : BD: Financials, 2021 and 2022
Table 89 : BD: Product Portfolio
Table 90 : BD: Key Developments, 2021-2023
Table 91 : Boston Scientific Corp.: Company Snapshot
Table 92 : Boston Scientific Corp.: Financials, 2021 and 2022
Table 93 : Boston Scientific Corp.: Product Portfolio
Table 94 : Boston Scientific Corp.: Key Developments, 2022
Table 95 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 96 : F. Hoffmann-La Roche Ltd.: Financials, 2021 and 2022
Table 97 : Johnson & Johnson Services Inc.: Company Snapshot
Table 98 : Johnson & Johnson Services Inc.: Financials, 2021 and 2022
Table 99 : Johnson & Johnson Services Inc.: Key Developments, 2022
Table 100 : Kindeva Drug Delivery: Company Snapshot
Table 101 : Medtronic plc: Company Snapshot
Table 102 : Medtronic plc: Financials, 2021 and 2022
Table 103 : Medtronic plc: Product Portfolio
Table 104 : Medtronic plc: Key Developments, 2023
Table 105 : Merck & Co. Inc.: Company Snapshot
Table 106 : Merck & Co. Inc.: Financials, 2021 and 2022
Table 107 : Novartis AG: Company Snapshot
Table 108 : Novartis AG: Financials, 2021 and 2022
Table 109 : Novartis AG: Key Developments, 2020-2022
Table 110 : Pfizer Inc.: Company Snapshot
Table 111 : Pfizer Inc.: Financials, 2021 and 2022
Table 112 : Sanofi S.A.: Company Snapshot
Table 113 : Sanofi S.A.: Financials, 2021 and 2022
Table 114 : Terumo Corp.: Company Snapshot
Table 115 : Terumo Corp.: Product Portfolio
Table 116 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 117 : Teva Pharmaceutical Industries Ltd.: Financials, 2021 and 2022
Table 118 : Acronyms Used in This Report
List of Figures
Summary Figure A : Global Market for Advanced Drug Delivery Systems, by Technology, 2020-2028
Summary Figure B : Global Market for Advanced Drug Delivery Systems, by Region, 2020-2028
Figure 1 : Conventional vs. Advanced Drug Delivery
Figure 2 : Conventional vs. Advanced Dosage Forms
Figure 3 : Evolution of Advanced Drug Delivery System, Since 1950s
Figure 4 : Global Markets and Technologies for Advanced Drug Delivery Systems Market Dynamics
Figure 5 : Categories of Therapeutic and Delivery Approaches
Figure 6 : Global Market for Advanced Drug Delivery Systems, by Technology
Figure 7 : Global Market Shares of Advanced Drug Delivery Systems, by Technology, 2022
Figure 8 : Global Market for Immediate Drug Release Technology, 2020-2028
Figure 9 : Extended Drug Delivery, by Type
Figure 10 : Global Market for Extended-Release Drug Delivery Systems, 2020-2028
Figure 11 : Global Market for Extended-Release Drug Delivery Systems, by Type, 2020-2028
Figure 12 : Global Market for Targeted-Release Drug Delivery Systems, 2020-2028
Figure 13 : Global Market for Delayed-Release Drug Delivery Systems, 2020-2028
Figure 14 : Global Market for Pulsatile Release Drug Delivery Systems, 2020-2028
Figure 15 : Global Market Shares of Advanced Drug Delivery Systems, by Route of Administration, 2022
Figure 16 : Oral Drug Delivery: Market Overview
Figure 17 : Global Market for Oral Advanced Drug Delivery Systems, 2020-2028
Figure 18 : Global Market for Parenteral/Injectable Advanced Drug Delivery Systems, 2020-2028
Figure 19 : Global Market for Advanced Transmucosal Drug Delivery Systems, 2020-2028
Figure 20 : Global Market for Advanced Transmucosal Drug Delivery Systems, by Type, 2020-2028
Figure 21 : Global Market for Advanced Implant Drug Delivery Systems, 2020-2028
Figure 22 : Global Market for Advanced Transdermal Drug Delivery Systems, 2020-2028
Figure 23 : Global Market for Advanced Topical Drug Delivery Systems, 2020-2028
Figure 24 : Global Market Shares of Advanced Drug Delivery Systems, by Drug Delivery Vehicle/Carrier, 2022
Figure 25 : Global Market for Nanoparticles for Advanced Drug Delivery Systems, 2020-2028
Figure 26 : Global Market for Monoclonal Antibodies for Advanced Drug Delivery Devices, 2020-2028
Figure 27 : Global Market for Liposomes for Advanced Drug Delivery Systems, 2020-2028
Figure 28 : Global Market for Polymeric Therapeutics for Advanced Drug Delivery Systems, 2020-2028
Figure 29 : Global Market for Polymeric Therapeutics for Advanced Drug Delivery Devices, 2020-2028
Figure 30 : Global Market Shares of Advanced Drug Delivery Systems, by Type of Polymeric Drugs, 2022
Figure 31 : Global Market for Prodrugs for Advanced Drug Delivery Devices, 2020-2028
Figure 32 : Global Market for Microparticles/Microspheres for Advanced Drug Delivery Devices, 2020-2028
Figure 33 : Global Market for Other Drug Delivery Vehicles/Carriers for Advanced Drug Delivery Systems, 2020-2028
Figure 34 : Global Market Shares of Advanced Drug Delivery Systems, by Application, 2022
Figure 35 : Global Market for Advanced Drug Delivery Systems in Oncology Applications, 2020-2028
Figure 36 : Global Market for Advanced Drug Delivery Systems in Inflammatory and Allergy Applications, 2020-2028
Figure 37 : Global Market for Advanced Drug Delivery Systems in Cardiovascular Applications, 2020-2028
Figure 38 : Global Market for Advanced Drug Delivery Systems in Ophthalmic Applications, 2020-2028
Figure 39 : Global Market for Advanced Drug Delivery Systems in Central Nervous System Applications, 2020-2028
Figure 40 : Global Market for Advanced Drug Delivery Systems in Hormone Replacement Therapy and Gynecological Applications, 2020-2028
Figure 41 : Influenza Burden Estimates in the U.S., October 2022 to April 2023
Figure 42 : Global Market for Advanced Drug Delivery Systems in Viral and Bacterial Diseases Applications, 2020-2028
Figure 43 : Global Market for Advanced Drug Delivery Systems in Diabetes Applications, 2020-2028
Figure 44 : Global Market for Advanced Drug Delivery Systems in Urology Applications, 2020-2028
Figure 45 : Global Market for Advanced Drug Delivery Systems in Gastrointestinal Disorder Applications, 2020-2028
Figure 46 : Global Market for Advanced Drug Delivery Systems in Dermatology Applications, 2020-2028
Figure 47 : Global Market for Advanced Drug Delivery Systems in Respiratory Applications, 2020-2028
Figure 48 : Global Market for Advanced Drug Delivery Systems in Other Therapeutic Applications, 2020-2028
Figure 49 : Global Market Shares of Advanced Drug Delivery Systems, by Region, 2022
Figure 50 : North American Market for Advanced Drug Delivery Systems, 2020-2028
Figure 51 : European Market for Advanced Drug Delivery Systems, 2020-2028
Figure 52 : Asia-Pacific Market for Advanced Drug Delivery Systems, 2020-2028
Figure 53 : Rest of the World Market for Advanced Drug Delivery Systems, 2020-2028
Figure 54 : ESG Pillars
Figure 55 : Advantages of ESG for Biopharmaceutical Companies
Figure 56 : ESG-Adoption Level Across All the Industries, Global, 2021 and 2022
Figure 57 : Hospitals: Sustainability Priorities
Figure 58 : Novartis: Major ESG Activities, 2022
Figure 59 : Patents Granted for Drug Delivery Systems, by Year, 2018-2022
Figure 60 : Major Pharmaceutical Players in the ADDS Market
Figure 61 : Major Medical Device Players in the ADDS Market
Figure 62 : Major CDMO Players in the ADDS Market
Figure 63 : Major CDMO Players in the ADDS Market
Figure 64 : Abbott: Revenue Share, by Business Unit, 2022
Figure 65 : Abbott: Revenue Share, by Region, 2022
Figure 66 : AbbVie Inc.: Financials, 2021 and 2022
Figure 67 : AbbVie Inc.: Revenue Share, by Business Unit, 2022
Figure 68 : AbbVie Inc.: Revenue Share, by Region, 2022
Figure 69 : BD: Financials, 2021 and 2022
Figure 70 : BD: Revenue Share, by Business Unit, 2022
Figure 71 : BD: Revenue Share, by Region, 2022
Figure 72 : Boston Scientific Corp.: Financials, 2021 and 2022
Figure 73 : Boston Scientific Corp.: Revenue Share, by Business Unit, 2022
Figure 74 : Boston Scientific Corp.: Revenue Share, by Country/Region, 2022
Figure 75 : F. Hoffmann-La Roche Ltd.: Financials, 2021 and 2022
Figure 76 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, 2022
Figure 77 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2022
Figure 78 : Johnson & Johnson Services Inc.: Financials, 2021 and 2022
Figure 79 : Johnson & Johnson Services Inc.: Revenue Share, by Business Segment, 2022
Figure 80 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, 2022
Figure 81 : Medtronic plc: Financials, 2021 and 2022
Figure 82 : Medtronic plc: Market Share, by Business Unit, 2022
Figure 83 : Medtronic plc: Market Share, by Region, 2022
Figure 84 : Merck & Co. Inc.: Financials, 2021 and 2022
Figure 85 : Merck & Co. Inc.: Revenue Share, by Business Unit, 2022
Figure 86 : Merck & Co. Inc.: Revenue Share, by Country/Region, 2022
Figure 87 : Novartis AG: Financials, 2021 and 2022
Figure 88 : Novartis AG: Revenue Share, by Business Unit, 2022
Figure 89 : Novartis AG: Revenue Share, by Region, 2022
Figure 90 : Pfizer Inc.: Financials, 2021 and 2022
Figure 91 : Pfizer Inc.: Revenue Share, by Business Unit, 2022
Figure 92 : Pfizer Inc.: Revenue Share, by Region, 2022
Figure 93 : Sanofi S.A.: Financials, 2021 and 2022
Figure 94 : Sanofi S.A.: Revenue Share, by Business Unit, 2022
Figure 95 : Sanofi S.A.: Revenue Share, by Region, 2022 (%)
Figure 96 : Teva Pharmaceutical Industries Ltd.: Financials, 2021 and 2022
Figure 97 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Unit, 2022
Figure 98 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security